SPINRAZA — FDA application NDA209531
Listed sponsor: BIOGEN · BIIB company profile · exact_unique
Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.
FDA application facts
| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
|---|---|---|---|---|---|---|---|---|
| 001 | SPINRAZA | NUSINERSEN SODIUM | SOLUTION | INTRATHECAL | EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) | Prescription | not listed | Yes |
| 002 | SPINRAZA | NUSINERSEN SODIUM | SOLUTION | INTRATHECAL | EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML) | Prescription | not listed | Yes |
| 003 | SPINRAZA | NUSINERSEN SODIUM | SOLUTION | INTRATHECAL | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | Prescription | not listed | Yes |
Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.
Orange Book patent and exclusivity listings
| Listing | Product | Descriptive date | Flags/code |
|---|---|---|---|
| Patent 7838657 | 001 | listed patent expiry date: 2027-07-11 | drug substance |
| Patent 7838657 | 002 | listed patent expiry date: 2027-07-11 | drug substance, drug product |
| Patent 7838657 | 003 | listed patent expiry date: 2027-07-11 | drug substance, drug product |
| Patent 9717750 | 001 | listed patent expiry date: 2030-06-17 | U-1942 |
| Patent 9717750 | 001 | listed patent expiry date: 2030-06-17 | U-2094 |
| Patent 9717750 | 001 | listed patent expiry date: 2030-06-17 | U-2093 |
| Patent 9717750 | 001 | listed patent expiry date: 2030-06-17 | U-1943 |
| Patent 9717750 | 002 | listed patent expiry date: 2030-06-17 | U-1943 |
| Patent 9717750 | 002 | listed patent expiry date: 2030-06-17 | U-2093 |
| Patent 9717750 | 002 | listed patent expiry date: 2030-06-17 | U-2094 |
| Patent 9717750 | 002 | listed patent expiry date: 2030-06-17 | U-1942 |
| Patent 9717750 | 003 | listed patent expiry date: 2030-06-17 | U-1943 |
| Patent 9717750 | 003 | listed patent expiry date: 2030-06-17 | U-2093 |
| Patent 9717750 | 003 | listed patent expiry date: 2030-06-17 | U-2094 |
| Patent 9717750 | 003 | listed patent expiry date: 2030-06-17 | U-1942 |
| Patent 8980853 | 001 | listed patent expiry date: 2030-11-24 | U-1941 |
| Patent 8980853 | 002 | listed patent expiry date: 2030-11-24 | U-1941 |
| Patent 8980853 | 003 | listed patent expiry date: 2030-11-24 | U-1941 |
| Patent 8361977 | 001 | listed patent expiry date: 2030-12-23 | drug substance, drug product |
| Patent 8361977 | 002 | listed patent expiry date: 2030-12-23 | drug substance, drug product |
| Patent 8361977 | 003 | listed patent expiry date: 2030-12-23 | drug substance, drug product |
| Patent 9926559 | 001 | listed patent expiry date: 2034-01-09 | U-1943 |
| Patent 10436802 | 001 | listed patent expiry date: 2035-09-11 | U-2094 |
| Patent 10436802 | 001 | listed patent expiry date: 2035-09-11 | U-1943 |
| Patent 10436802 | 001 | listed patent expiry date: 2035-09-11 | U-1941 |
| Patent 10436802 | 001 | listed patent expiry date: 2035-09-11 | U-2093 |
| Patent 10436802 | 001 | listed patent expiry date: 2035-09-11 | U-1944 |
| Patent 10436802 | 001 | listed patent expiry date: 2035-09-11 | U-1942 |
| Patent 12013403 | 001 | listed patent expiry date: 2036-03-04 | U-1941 |
| Patent 12013403 | 001 | listed patent expiry date: 2036-03-04 | U-1942 |
| Patent 12013403 | 001 | listed patent expiry date: 2036-03-04 | U-1943 |
| Patent 12013403 | 001 | listed patent expiry date: 2036-03-04 | U-1944 |
| Patent 12013403 | 001 | listed patent expiry date: 2036-03-04 | U-2093 |
| Patent 12013403 | 001 | listed patent expiry date: 2036-03-04 | U-2094 |
| Exclusivity NS | 002 | listed exclusivity date: 2029-03-27 | FDA code as listed |
| Exclusivity NS | 003 | listed exclusivity date: 2029-03-27 | FDA code as listed |
Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.
Compound cross-links
- NUSINERSEN · UNII 5Z9SP3X666 · no lmmol compound match
Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.
Related pages
Sponsor company · FDA-approved application index
Peer clusters: No published peer-cluster link for this sponsor.
Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.
Regulatory listing data as published by FDA; not medical or investment advice.